Contact
searchSearch
HMP Global
Video

Evidence Supporting Treatment in Challenging AAA Anatomy: Gustavo Oderich, MD, Robert Rhee, MD, and Sukgu Han, MD Discuss Clinical Trial Data

Gustavo S. Oderich, MD
Robert Rhee, MD
Sukgu Han, MD
07/01/2026

Experts review pivotal trial design and outcomes, sharing clinical perspectives on treating short and highly angulated neck anatomies with the GORE® EXCLUDER® Conformable device.

Related Content

Dr Kak Khee Yeung speaks at ISET 2026.
ISET 2026
Can AI Be of Value in Predicting Type B Dissection Progression Over Time?
04/16/2026
Kak Khee Yeung, MD, PhD
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD,...
04/16/2026
Vascular Disease Management
Dr Jacques Busquet speaks at ISET 2026.
ISET 2026
The Mystery of Post-EVAR Endotension
03/26/2026
Jacques Busquet, MD
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned...
03/26/2026
Vascular Disease Management
Interview
Confronting the Gender Gap in AAA Care: Women Face Worse Outcomes and What Needs to Change
02/18/2026
Jon Matsumura, MD
Despite advances, women with AAA continue to experience disproportionately higher mortality rates and remain significantly underrepresented in clinical trials.
Despite advances, women with AAA continue to experience disproportionately higher mortality rates and remain significantly underrepresented in clinical trials.
Despite advances, women with AAA...
02/18/2026
Vascular Disease Management
John S. Pellerito, MD
ISET 2026
CEUS in Vascular Imaging—EVAR Follow-Up and Beyond
02/09/2026
John S. Pellerito, MD
John S. Pellerito, MD, began his Monday morning session at ISET 2026 with a pragmatic message for vascular specialists: contrast-enhanced ultrasound (CEUS) is no longer a niche add-on in the vascular lab.
John S. Pellerito, MD, began his Monday morning session at ISET 2026 with a pragmatic message for vascular specialists: contrast-enhanced ultrasound (CEUS) is no longer a niche add-on in the vascular lab.
John S. Pellerito, MD, began his...
02/09/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

JANE-2 project
Green Paper
Tumor Ablation Review Maps Next Phase of Cancer Care
08/14/2026
Laura Simson, MA
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
The EU Joint Action Networks of...
08/14/2026
Vascular Disease Management
Intravascular Lithotripsy
FastWave Medical Gains FDA IDE Approval to Begin Pivotal Trial of Artero Peripheral IVL System
08/12/2026
The U.S. pivotal study will evaluate FastWave's electric IVL system in patients with peripheral artery disease.
The U.S. pivotal study will evaluate FastWave's electric IVL system in patients with peripheral artery disease.
The U.S. pivotal study will...
08/12/2026
Cath Lab Digest
Embolic Technologies
Fluidx Medical Closes Financing to Advance Next-Generation Embolic Platform
08/12/2026
SALT LAKE CITY, Utah — August 6, 2026 — Fluidx Medical Technology, Inc., a developer of innovative embolic technologies, today announced the successful closing of financing to fund development and growth. The financing follows significant...
SALT LAKE CITY, Utah — August 6, 2026 — Fluidx Medical Technology, Inc., a developer of innovative embolic technologies, today announced the successful closing of financing to fund development and growth. The financing follows significant...
SALT LAKE CITY, Utah — August 6,...
08/12/2026
Vascular Disease Management
Phase 3 Randomized Clinical Trial
TACE Plus Ablation Improves Survival in Unresectable HCC Compared With TACE Alone
08/11/2026
Laura Simson, MA
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency...
08/11/2026
Vascular Disease Management
CANSCAN Participant using VxWave
autonomous Ultrasound Imaging
Vexev Raises $6M to Accelerate U.S. Commercialization of Autonomous Vascular Imaging Platform
08/10/2026
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
The announcement follows...
08/10/2026
Cath Lab Digest
Press Release
Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device
07/24/2026
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026...
07/24/2026
Vascular Disease Management
Thrombectomy
THUNDER Study Demonstrates Penumbra’s THUNDERBOLT is Safe and Effective for Stroke Care
07/22/2026
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif....
07/22/2026
Cath Lab Digest
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management
Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use